Muravyov A V, Zaitsev L G, Muravyov A A, Yakusevich V V, Sirotkina A M
Department of Biol. and Med. Problems, Yaroslavl University, Russia.
Clin Hemorheol Microcirc. 1998 Jul;18(2-3):185-90.
In this study, the effect of the angiotensin-converting-enzyme inhibitor (ACE inhibitor) Ramipril (5 mg/day) and calcium antagonist Isradipin (5 mg/day) treatment of two groups of hypertensive patients (n = 22 in each of group) was evaluated. The parameters of the hemorheological profile (blood and plasma viscosity, red blood cell aggregation and deformation, plasma protein concentration and its osmolality, hematocrit and ratio of Hct/blood viscosity) were measured in basal conditions (before treatment) and after 3 weeks of treatment. The patients showed some increased blood, plasma viscosity, RBC aggregability and fibrinogen concentration in basal conditions. In both groups of patients, three main parameters of the hemorheological profile (plasma viscosity, Hct and RBC aggregation) decreased after treatment. No significant changes in red cell deformability was found. In conclusion, ACE inhibition with Ramipril and calcium channel blocking with Isradipin lead to a moderate improvement of blood rheology in patients with hypertension. This may be explained by the pronounced vasodilatatory effect of ACE inhibitor and calcium antagonist, though their acting mechanism is different.
在本研究中，评估了血管紧张素转换酶抑制剂（ACE抑制剂）雷米普利（5毫克/天）和钙拮抗剂伊拉地平（5毫克/天）对两组高血压患者（每组n = 22）的治疗效果。在基础状态（治疗前）和治疗3周后，测量血液流变学指标（血液和血浆粘度、红细胞聚集和变形、血浆蛋白浓度及其渗透压、血细胞比容以及血细胞比容/血液粘度比值）。患者在基础状态下血液、血浆粘度、红细胞聚集性和纤维蛋白原浓度有所升高。两组患者治疗后血液流变学的三个主要指标（血浆粘度、血细胞比容和红细胞聚集）均下降。未发现红细胞变形性有显著变化。总之，雷米普利抑制ACE以及伊拉地平阻断钙通道可使高血压患者的血液流变学得到适度改善。这可能是由于ACE抑制剂和钙拮抗剂具有显著的血管舒张作用，尽管它们的作用机制不同。
